Director/PDMR Shareholding

Venture Life Group PLC
26 June 2023
 

26 June 2023

VENTURE LIFE GROUP PLC

("Venture Life" "VLG" or the "Group")

Director Dealings

Venture Life Group plc (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, announces that Carl Dempsey, Non-Executive Director, today purchased 100,000 ordinary shares of 0.3p each in the Company ("Ordinary Shares") at a price of 38.00 pence per Ordinary Share.

Following this purchase, Mr Dempsey beneficially holds 148,500 Ordinary Shares representing 0.12 per cent. of the Company's issued share capital.

 

For further information, please contact:

 

Venture Life Group PLC

+44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer


 

Cenkos Securities plc (Nomad and Broker)

 

+44 (0) 20 7397 8900

Stephen Keys / Camilla Hume

 

Russell Kerr / Michael Johnson (Sales)

 

 

Singer Capital Markets (Joint Broker)

Shaun Dobson / Alaina Wong  (Corporate Finance)                                       

Jonathan Dighe (Sales)

 

 

+44 (0) 20 7496 3000

 

 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, The Netherlands and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare, fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing.

 

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands, these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

 

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies for consumer healthcare products, primarily medical devices.

 

 

The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Carl Dempsey

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Director

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Venture Life Group plc

b)

 

LEI

 

 

213800S8CZUPLAB2KC70

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

 

Identification code

 

 

Ordinary Shares of 0.3p each in Venture Life Group plc

 

 

 

GB00BFPM8908

b)

 

Nature of the transaction

 

 

Purchase of ordinary shares

c)

 

Price(s) and volume(s)

 

 

100,000 ordinary shares at 38.00 pence per share

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

n/a

 

 

 

 

 

 

 

e)

 

Date of the transaction

 

 

26 June 2023

f)

 

Place of the transaction

 

 

London Stock Exchange

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100